Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) recently conducted a public consultation on the proposal to reclassify Gina vaginal tablets, which contain 10 mcg of estradiol, from a prescription only medicine (POM) to a pharmacy (P) medicine.1 The proposed indication for the P product is ‘treatment of vaginal atrophy due to oestrogen deficiency in postmenopausal women aged 50 years and above, who have not had a period for at least 1 year’.2 This is the first hormonal product aimed at relief of local symptoms resulting from the menopause to be considered for this reclassification and is a welcome step forward in self-care.
Vulvovaginal atrophy is associated with reduced oestrogen levels in vaginal tissue and is often accompanied by symptoms that include dryness, irritation of the vulva, burning sensation, dysuria, dyspareunia and vaginal discharge.3 Such symptoms can have a significant impact on a woman’s quality of …
Competing interests None declared. Refer to the online supplementary files to view the ICMJE form(s).
Provenance and peer review Commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.